BridgeBio Pharma, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2017 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
BridgeBio Pharma, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2017 to 2023.
  • BridgeBio Pharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $27.1M, a 0.36% decline year-over-year.
  • BridgeBio Pharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $115M, a 14% increase year-over-year.
  • BridgeBio Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $115M, a 22.6% increase from 2022.
  • BridgeBio Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $93.8M, a 11.1% decline from 2021.
  • BridgeBio Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $106M, a 80.6% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $115M +$21.2M +22.6% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-22
2022 $93.8M -$11.7M -11.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-22
2021 $106M +$47.1M +80.6% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-22
2020 $58.5M +$37.1M +174% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 $21.4M +$15.3M +252% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-25
2018 $6.07M +$4.23M +230% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 $1.84M Jan 1, 2017 Dec 31, 2017 10-K 2020-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.